CURI Earnings

CURI reported its earnings on 2026-03-23, showcasing a revenue of against an estimate of 18.40M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.04 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following CURI's earnings announcement on 2026-03-23, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, CURI's stock price tends to shift by an average of 4.44% in the 10 days leading up to earnings and 25.43% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate CURI's annual revenue to reach 18.91M, while the EPS is projected at -0.01. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CURI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CURI's stock price typically moves by 4.44% in the 10 days before its earnings and 25.43% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.01 and revenue of 18.91M.

The earnings call presented strong financial performance, with significant growth in licensing revenue and improved gross margins. Despite a net loss, the company maintains a strong balance sheet with no debt. The Q&A section revealed plans for future growth through strategic hires and new partnerships, addressing concerns about revenue lumpiness. While some responses were vague, overall sentiment was positive with strong revenue growth projections and strategic expansions in AI licensing and subscription services.